Moreover, the risk score can effectively predict the 1, 3, and 5-year OS rate of patients with pan-gliomas (Figure 4F and Supplementary Figure 1C, 1D), LGG (Supplementary Figure 2C, 2G, 2K), GBM (Supplementary Figure 2D, 2H, 2L), IDH mutation (Supplementary Figures 3C, 4C, 4I) and IDH wildtype (Supplementary Figures 3D, 4D, 4J) in the three cohorts (Supplementary Table 6). This evidence concerns the gene IDH1 and central nervous system cancer.